The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells
Open accessThe DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Abstract
Retinoic acid is an embryonic morphogen and dietary factor that demonstrates chemotherapeutic efficacy in inducing maturation in leukemia cells. Using HL60 model human myeloid leukemia cells, where all-trans retinoic acid (RA) induces granulocytic differentiation, we developed two emergent RA-resistant HL60 cell lines which are characterized by loss of RA-inducible G1/G0 arrest, CD11b expression, inducible oxidative metabolism and p47(phox) expression. However, RA-treated RA-resistant HL60 continue to exhibit sustained MEK/ERK activation, and one of the two sequentially emergent resistant lines retains RA-inducible CD38 expression. Other signaling events that define the wild-type (WT) response are compromised, including c-Raf phosphorylation and increased expression of c-Cbl, Vav1, and the Src-family kinases (SFKs) Lyn and Fgr. As shown previously in WT HL60 cells, we found that the SFK inhibitor PP2 significantly increases G1/G0 cell cycle arrest, CD38 and CD11b expression, c-Raf phosphorylation and expression of the aforementioned regulators in RA-resistant HL60. The resistant cells were potentially incapable of developing inducible oxidative metabolism. These results motivate the concept that RA resistance can occur in steps, wherein growth arrest and other differentiation events may be recovered in both emergent lines. Investigating the mechanistic anomalies in resistant cell lines is of therapeutic significance and helps to mechanistically understand the response to retinoic acid's biological effects in WT HL60 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the pharmacological inhibition of p-Src with a PP2 inhibitor [28, 29] causes MAPK inhibition in these cell lines (Figure 1D).”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520 · cited 1×
“PP2 is a pyrazolopyrimidine compound that is a potent inhibitor for all SFK members [25,26].”
BackgroundRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284 · cited 4×
“Phosphorylation at canonical c-Raf activating sites such as S338 and Y340/341 [33,34] cannot be detected in RA-induced WT HL60 cells [35].”
BackgroundInfluentialInduction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
Breitman, T. R., Selonick, S. E., & Collins, S. J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2936 · Cited by 1,966 · cited 1×
“Also following differentiation, RA-treated HL60 cells display an inducible reactive oxygen species (ROS) response, which is a late, functional marker of mature myeloid cells [19,20].”
BackgroundDiscovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939 · cited 1×
“PP2 is a pyrazolopyrimidine compound that is a potent inhibitor for all SFK members [25,26].”
BackgroundCollins, S. (1987) · Blood · doi:10.1182/blood.v70.5.1233.1233 · Cited by 1,190 · cited 1×
“being induced to differentiate into monocytes or granulocytes [8,9].”
BackgroundCoordinating ERK/MAPK signalling through scaffolds and inhibitors
Kolch, W. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1743 · Cited by 1,070 · cited 2×
“However, PP2-induced c-Raf phosphorylation, despite a decrease in MEK and ERK phosphorylation, is consistent in that c-Raf has defined ERK-independent functions [34,52].”
BackgroundRetinoids and their receptors in differentiation, embryogenesis, and neoplasia
De Luca, L. M. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.14.1661245 · Cited by 843
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633 · cited 1×
“The S289/296/301 sites are retrophosphorylated by ERK; whether this phosphorylation is inhibitory [40] or activating [41] is subject to debate.”
BackgroundRetinoids, Retinoic Acid Receptors, and Cancer
Tang, X.-H., & Gudas, L. J. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130303 · Cited by 596
Collins, S. J., Ruscetti, F. W., Gallagher, R. E., & Gallo, R. C. (1979) · The Journal of experimental medicine · doi:10.1084/jem.149.4.969 · Cited by 585 · cited 3×
“have been a durable experimental system since the late 1970s [6].”
BackgroundMethodRetinoid pathway and cancer therapeutics
Bushue, N., & Wan, Y.-J. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.003 · Cited by 373 · cited 1×
“therapeutic roles in other cancers and diseases [3,4].”
BackgroundIdentification of the major phosphorylation sites of the Raf-1 kinase
Morrison, D. K., Heidecker, G., Rapp, U. R., & Copeland, T. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85336-x · Cited by 328
Chen, J., Fujii, K., Zhang, L., Roberts, T., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316 · cited 1×
“c-Raf plays a role in apoptosis that is independent of its catalytic activity [34,53,54] and c-Raf may serve scaffolding functions [52].”
BackgroundMEK kinase activity is not necessary for Raf-1 function
Huser, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1940 · Cited by 310 · cited 1×
“c-Raf plays a role in apoptosis that is independent of its catalytic activity [34,53,54] and c-Raf may serve scaffolding functions [52].”
BackgroundYen, A., Roberson, M. S., Varvayanis, S. S., & Lee, A. T. (1998) · PubMed · Cited by 258
Self-citation(1995) · PubMed · Cited by 215
The HL60 cell line: a model system for studying human myeloid cell differentiation.
Birnie, G. D. (1988) · Europe PMC (PubMed Central) · Cited by 185
Robertson, K., Emami, B., & Collins, S. (1992) · Blood · doi:10.1182/blood.v80.8.1885.1885 · Cited by 179 · cited 1×
“RA resistance has previously been found to be attributable to mutation of the RARa gene [30,31,32].”
BackgroundShao, W., Benedetti, L., Lamph, W. W., Nervi, C., & Miller, W. H. (1997) · Blood · doi:10.1182/blood.v89.12.4282 · Cited by 147
A critical role for Lyn in acute myeloid leukemia
Dos Santos, C., Demur, C., Bardet, V., Prade-Houdellier, N., Payrastre, B., & Récher, C. (2008) · Blood · doi:10.1182/blood-2007-04-082099 · Cited by 141
Pratt, M. A., Kralova, J., & McBurney, M. W. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6445 · Cited by 132
Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association
Kubicek, M., Pacher, M., Abraham, D., Podar, K., Eulitz, M., & Baccarini, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108733200 · Cited by 124 · cited 2×
“This is consistent with our data, as we see an increase in S259 phosphorylation, which inhibits canonical Ras-induced (membrane-initiated) c-Raf activation [37].”
BackgroundResultPhosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition
Tran, N. H., & Frost, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210318200 · Cited by 116 · cited 2×
“Phosphorylation at canonical c-Raf activating sites such as S338 and Y340/341 [33,34] cannot be detected in RA-induced WT HL60 cells [35].”
BackgroundCRAF Autophosphorylation of Serine 621 Is Required to Prevent Its Proteasome-Mediated Degradation
Noble, C., Mercer, K., Hussain, J., Carragher, L., Giblett, S., Hayward, R., Patterson, C., Marais, R., & Pritchard, C. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.026 · Cited by 94 · cited 1×
“The constitutively phosphorylated S621 site appears to be a stability site that maintains the kinase activity of c-Raf [36] and prevents c-Raf degradation [39].”
BackgroundEnhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis
Opavsky, M. A., Martino, T., Rabinovitch, M., Penninger, J., Richardson, C., Petric, M., Trinidad, C., Butcher, L., Chan, J., & Liu, P. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213971 · Cited by 91 · cited 1×
“Interestingly, PP2 treatment in both R38+ and R382 results in a decrease of ERK phosphorylation, an effect that has been documented in other cell lines [49,50,51].”
BackgroundBalan, V., Leicht, D. T., Zhu, J., Balan, K., Kaplun, A., Singh-Gupta, V., Qin, J., Ruan, H., Comb, M. J., & Tzivion, G. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1123 · Cited by 90 · cited 1×
“The S289/296/301 sites are retrophosphorylated by ERK; whether this phosphorylation is inhibitory [40] or activating [41] is subject to debate.”
BackgroundTherapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth
Roginskaya, V. Y., Zuo, S., Caudell, E. G., Nambudiri, G., Kraker, A. J., & Corey, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401429 · Cited by 90 · cited 1×
“PP2 has previously been shown to reduce proliferation in myeloid blasts [46], and other cell types [43,47].”
BackgroundYen, A., Forbes, M. E., DeGala, G., & Fishbaugh, J. (1987) · PubMed · Cited by 80
Self-citationExpression of src family genes during monocytic differentiation of HL-60 cells
Katagiri, K., Katagiri, T., Koyama, Y., Morikawa, M., Yamamoto, T., & Yoshida, T. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.701 · Cited by 80 · cited 2×
“Lyn and Fgr are the predominant SFKs in myeloid leukemia cells [27,28] and Lyn binds to CD38 [15].”
BackgroundCongleton, J., MacDonald, R., & Yen, A. (2011) · Leukemia · doi:10.1038/leu.2011.390 · Cited by 69 · cited 13×
“This is disparate of the WT HL60 data reported [23], where PP2 treatment had no effect on MEK or ERK activation.”
BackgroundMethodResultInfluentialSelf-citationPhosphatase and Feedback Regulation of Raf-1 Signaling
Dhillon, A. S., von Kriegsheim, A., Grindlay, J., & Kolch, W. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3593 · Cited by 63 · cited 1×
“The S259 site is putatively an inhibitory site [36] that prevents relocation of c-Raf to the plasma membrane [37,38] and thus prevents its participation in membrane-initiated signaling events.”
BackgroundSpreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Di Stefano, A., Tintori, C., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-9873com · Cited by 63 · cited 1×
“PP2 has previously been shown to reduce proliferation in myeloid blasts [46], and other cell types [43,47].”
BackgroundLi, Z., Hosoi, Y., Cai, K., Tanno, Y., Matsumoto, Y., Enomoto, A., Morita, A., Nakagawa, K., & Miyagawa, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.193 · Cited by 60 · cited 1×
“Interestingly, PP2 treatment in both R38+ and R382 results in a decrease of ERK phosphorylation, an effect that has been documented in other cell lines [49,50,51].”
BackgroundFontana, J. A., Colbert, D. A., & Deisseroth, A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3863 · Cited by 57 · cited 1×
“HL60 cells are bipotent [7] myelomonocytic precursors, capable of”
BackgroundKobayashi, T., Tsunawaki, S., & Seguchi, H. (2001) · Redox Report · doi:10.1179/135100001101536003 · Cited by 56 · cited 2×
“Also following differentiation, RA-treated HL60 cells display an inducible reactive oxygen species (ROS) response, which is a late, functional marker of mature myeloid cells [19,20].”
BackgroundZumaquero, E., Muñoz, P., Cobo, M., Lucena, G., Pavón, E. J., Algíbez, A. M., Navarro, P., García-Pérez, A., Ariza, A., Malavasi, F., et al. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.05.032 · Cited by 56 · cited 3×
“Lyn and Fgr are the predominant SFKs in myeloid leukemia cells [27,28] and Lyn binds to CD38 [15].”
BackgroundMehta, K., McQueen, T., Manshouri, T., Andreeff, M., Collins, S., & Albitar, M. (1997) · Blood · doi:10.1182/blood.v89.10.3607 · Cited by 56 · cited 1×
“extremely early marker of RA-induced differentiation [12,13], is a nexus for many signaling proteins also upregulated with RA treatment in these cells.”
BackgroundWang, J., & Yen, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708471200 · Cited by 55 · cited 3×
“Sustained activation of the Raf/MEK/ERK proteins is a longknown feature of RA-treated HL60, and direct inhibition of MEK (and subsequently ERK as well as c-Raf) using PD98095 has been shown to abolish RA-induced differentiation of HL60 [21,22].”
BackgroundMethodSelf-citationShen, M., & Yen, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1058 · Cited by 52 · cited 4×
“5610(6) cells were immunostained with phycoerythrin (PE)conjugated anti-CD38 antibody and allophycocyanin (APC)conjugated anti-CD11b antibody (BD Pharmingen, San Jose, CA) and analyzed by flow cytometry (BD LSRII flow cytometer, BD Biosciences, San Jose, CA) as described previously [17].”
BackgroundMethodInfluentialSelf-citationDasatinib promotes ATRA-induced differentiation of AML cells
Kropf, P. L., Wang, L., Zang, Y., Redner, R. L., & Johnson, D. E. (2009) · Leukemia · doi:10.1038/leu.2009.267 · Cited by 45 · cited 1×
“Although both Lyn and Fgr are upregulated with RA treatment in HL60 cells, Lyn is the predominant SFK phosphorylated in RA-induced HL60 cells [23,29].”
BackgroundLamkin, T. J., Chin, V., Varvayanis, S. S., Smith, J. L., Sramkoski, R. M., Jacobberger, J. W., & Yen, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20745 · Cited by 44 · cited 2×
“extremely early marker of RA-induced differentiation [12,13], is a nexus for many signaling proteins also upregulated with RA treatment in these cells.”
BackgroundMethodSelf-citationBertagnolo, V., Brugnoli, F., Marchisio, M., Celeghini, C., Carini, C., & Capitani, S. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.09.013 · Cited by 42 · cited 1×
“Vav1, expressed solely in hematopoietic cells, is upregulated in RA-induced HL60 cells [44] and serves a cytoplasmic role as an adaptor and guanine nucleotide exchange factor (GEF), as well as a nuclear role as a transcription factor and cytoskeletal remodeling protein [44,45].”
BackgroundBrugnoli, F., Lambertini, E., Varin‐Blank, N., Piva, R., Marchisio, M., Grassilli, S., Miscia, S., Capitani, S., & Bertagnolo, V. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.004 · Cited by 42 · cited 1×
“Vav1, expressed solely in hematopoietic cells, is upregulated in RA-induced HL60 cells [44] and serves a cytoplasmic role as an adaptor and guanine nucleotide exchange factor (GEF), as well as a nuclear role as a transcription factor and cytoskeletal remodeling protein [44,45].”
BackgroundSignal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ
Yamaguchi, K., Richardson, M. D., Bigner, D. D., & Kwatra, M. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1030-3 · Cited by 38 · cited 1×
“Interestingly, PP2 treatment in both R38+ and R382 results in a decrease of ERK phosphorylation, an effect that has been documented in other cell lines [49,50,51].”
BackgroundMiranda, M. B., Redner, R. L., & Johnson, D. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0514 · Cited by 36 · cited 1×
“This effect was reported previously in both HL60 and NB4 cells [24].”
BackgroundShen, M., & Yen, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014241 · Cited by 28 · cited 5×
“Transfection of mutant G306E c-Cbl, which cannot interact with CD38, into HL60 cells eradicates RA-induced differentiation and MAPK signaling [14].”
BackgroundMethodInfluentialSelf-citationRetinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells
Smith, J., Bunaciu, R. P., Reiterer, G., Coder, D. M., George, T. C., Asaly, M., & Yen, A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.03.004 · Cited by 27 · cited 1×
“Phosphorylation at canonical c-Raf activating sites such as S338 and Y340/341 [33,34] cannot be detected in RA-induced WT HL60 cells [35].”
BackgroundSelf-citationLee, M., Kim, J., & Anderson, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403132200 · Cited by 27 · cited 1×
“PP2 was reported to enhance Ras-independent Raf phosphorylation [48].”
BackgroundVav promotes differentiation of human tumoral myeloid precursors
Bertagnolo, V., Brugnoli, F., Mischiati, C., Sereni, A., Bavelloni, A., Carini, C., & Capitani, S. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.001 · Cited by 25 · cited 1×
“Ectopic overexpression of either Vav1 [16], c-Cbl [17] or Slp76 combined with c-FMS [18] has been shown to enhance RA-induced differentiation in HL60.”
BackgroundYen, A., Varvayanis, S. S., Smith, J. L., & Lamkin, T. J. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2005.09.020 · Cited by 22 · cited 2×
“Ectopic overexpression of either Vav1 [16], c-Cbl [17] or Slp76 combined with c-FMS [18] has been shown to enhance RA-induced differentiation in HL60.”
BackgroundMethodSelf-citationLocation and Functional Significance of Retinol-binding Sites on the Serine/Threonine Kinase, c-Raf
Hoyos, B. E., Jiang, S., & Hämmerling, U. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412695200 · Cited by 22 · cited 1×
“It is known that retinoids can directly bind kinases like PKC and even c-Raf [42], suggesting that RA can affect signaling independent of its transcriptional effects.”
BackgroundKingsley, E. C., Durie, B. G. M., & Garewal, H. S. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-34594-7 · Cited by 19
Doré, B. T., & Momparler, R. L. (1996) · Leukemia Research · doi:10.1016/0145-2126(96)00043-4 · Cited by 19
Goodsell, D. S. (2003) · RCSB Protein Data Bank · doi:10.2210/rcsb_pdb/mom_2003_7 · Cited by 15
Lee, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.067 · Cited by 14 · cited 3×
“PP2 has previously been shown to reduce proliferation in myeloid blasts [46], and other cell types [43,47].”
Background
Cited by
Acute promyelocytic leukemia (APL): a review of the literature
Jimenez, J. J., Chale, R. S., Abad, A. C., & Schally, A. V. (2020) · Oncotarget · doi:10.18632/oncotarget.27513 · Cited by 136
“Several ATRAresistant HL-60 cell lines have been isolated [38, 39].”
BackgroundWhy Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids
Chlapek, P., Sláviková, V., Mazánek, P., Štěrba, J., & Veselská, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010132 · Cited by 73
“For example, such an effect on retinoid-resistant leukemia cells was achieved with MEK inhibitor or Src-family kinase inhibitors under in vitro conditions [73,74].”
BackgroundAn Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program
Tasseff, R. A., Jensen, H. A., Congleton, J., Dai, D. L., Rogers, K. V., Sagar, A., Bunaciu, R. P., Yen, A., & Varner, J. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-14523-5 · Cited by 61
Self-citationWehinger, S., Ortiz, R. J., Díaz, M. I., Aguirre, A., Valenzuela, M., Llanos, P., McMaster, C. R., Leyton, L., & Quest, A. F. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.021 · Cited by 50
Lainey, É., Wolfromm, A., Sukkurwala, A. Q., Micol, J., Fenaux, P., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Cell Cycle · doi:10.4161/cc.26016 · Cited by 45
“Moreover, the SFK inhibitor PP2 has recently been shown to rescue inducible differentiation in emergent ATRA-resistant myeloblastic leukemia cells, confirming the important role of SFKs in this process.(46) The detailed molecular mechanisms whereby erlotinib exerts differentiation-inducing effects remain largely elusi…”
Background
Metadata
- Authors
- Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A.
- Affiliations
- Cornell University (US)
- Corresponding author
- Yen, Andrew
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-03-15
- Volume
- 8
- Issue
- 3
- Pages
- e58621
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3598855
- OpenAlex
- W1995083340
- Cited by
- 18
- References
- 57
- Citations by year
- 2025: 2 · 2020: 3 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 3
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (0846876, CAREER)
- New York State Department of Health
- New York State Stem Cell Science
- National Institutes of Health
- National Cancer Institute (CA033505, CA152870, R01CA152870, R01CA033505)
- Division of Chemical, Bioengineering, Environmental, and Transport Systems
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- retinoic acid resistance, myeloblastic leukemia, HL-60 cells, PP2, Src family kinases, granulocytic differentiation, MEK/ERK signaling, CD38, CD11b, G1 cell cycle arrest, oxidative metabolism, p47phox, Vav1, c-Cbl, Fgr, Lyn kinase
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Humans, Leukemia, Myeloid, Membrane Glycoproteins, Proto-Oncogene Proteins, Pyrimidines, Tretinoin, Gene Expression Regulation, Leukemic, Resting Phase, Cell Cycle, HL-60 Cells, Drug Resistance, Neoplasm, src-Family Kinases, NADPH Oxidases, CD11b Antigen, Proto-Oncogene Proteins c-cbl, Proto-Oncogene Proteins c-vav, ADP-ribosyl Cyclase 1, G1 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.